Browsing Tag
Septerna
2 posts
What this Phase 1 milestone reveals about the next wave of GPCR-driven endocrine therapeutics
What does Septerna’s Phase 1 milestone mean for GPCR-driven endocrine innovation? Read how SEP-479 could reshape biotech strategy and market sentiment.
Novo Nordisk and Septerna forge $2.2bn GPCR deal to develop oral therapies for obesity and diabetes
Novo Nordisk partners with Septerna in a $2.2B deal to develop oral GPCR therapies for obesity and diabetes. Explore the full stock sentiment and deal impact.